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Advanced oxidation protein products as a novel marker of oxidative
stress in uremia. Evidence suggests an imbalance between antioxidant and
oxidant-generating systems resulting in oxidative stress in uremic patients.
As plasma proteins are critical targets for oxidants, we developed a novel
spectrophotometric assay which allows to detect advanced oxidation
protein products (AOPP) in uremic plasma. By size-exclusion chromatog-
raphy AOPP are retrieved in two distinct peaks at 600 and below 80 kDa
in ureniic plasma, while no such peaks are found in control plasma.
Further biochemical characterization revealed that AOPP are carried by
oxidized plasma proteins, especially albumin and do not have oxidant
properties. AOPP increased in a dose-dependent manner following in vitro
exposure of plasma or purified human serum albumin (HSA) to hypochlo-
rous acid. Advanced glycation end products of human serum albumin
(AGE-HSA) also increased AOPP levels. In vivo, plasma level of AOPP
was the highest in patients on hemodialysis, followed by those on
peritoneal dialysis and by undialyzed patients with advanced chronic renal
failure. AOPP levels correlated with plasma concentrations of dityrosine
and AGE-pentosidine, as indices of oxidant-mediated protein damage, but
not with thiobarbituric reactive substances as lipid peroxidation markers.
A close correlation was also found between AOPP and neopterin levels,
suggesting that AOPP could be part in the monocyte-mediated inflamma-
tory disorders associated with uremia. In conclusion, we propose the
measurement of AOPP as a reliable marker to estimate the degree of
oxidant-mediated protein damage in uremic patients and to predict the
potential efficacy of therapeutic strategies aimed at reducing such an
oxidative stress.
Chronic renal failure (CRF) is associated with a multifactorial
immuno-inflammatory syndrome that occurs early in the course of
renal failure, worsens with its progression and culminates on
maintenance dialysis therapy, as recently reviewed in [1]. Among
the mechanisms involved in such uremia-related immuno-inflam-
matory disorders, a dysregulation in the balance between pro-
inflammatory cytokines and their inhibitors has recently been
demonstrated [2, 3]. It has also been proposed that increased
production of oxidants by phagoeytes, in the face of defective
antioxidant defenses, results in chronic oxidative stress that
further enhances the inflammatory state [4]. This has been
especially well documented in patients on maintenance hemodi-
alysis (HD) in whom blood interaction with bioincompatible
membranes triggers circulating neutrophils to produce numerous
reactive oxygen species, including superoxide anion, hydrogen
peroxide, hydroxyl radical and hypochlorous acid [5—10]. In this
setting, the oxidant scavenging potential of plasma components is
likely to be overwhelmed [11] as evidenced by a decrease in
ascorbic acid [12], superoxide dismutase [13] and the glutathione
system [14—16] in both pre-dialysis and HD patients. The resulting
oxidative stress could be an important event in the pathogenesis of
atherosclerosis [17], which still is the leading cause of morbidity
and mortality in uremic patients [18—20].
With respect to the markers of such oxidative stress, some
reports have shown that plasma level of malondialdehyde (MDA),
a byproduct of lipid peroxidation which reacts with thiobarbituric
acid (TBA) and is also referred to as TBA-reacting substances
(TBARS), is elevated in both dialyzed and undialyzed CRF
patients [16, 21, 22].
In contrast to lipids, the reactions of proteins with various
oxidants have not been extensively studied, and it was sometimes
assumed that proteins are not particularly susceptible to free
radical damage. This assumption has been invalidated in recent
years, and it is now clear that amino acids, peptides, and proteins
are vulnerable to attacks by a variety of free radicals and related
oxidants [23, 241. Oxidation of particularly sensitive amino acid
residues, aggregation, cross linking, fragmentation, as well as loss
of enzymatic or other functional properties are but a few of the
documented examples. Interestingly, we have previously shown
that exposure of 32-microglobulin to hydroxyl radicals leads to
aggregation and dityrosine formation [25], which may be of
pathophysiological relevance in view of the f32-microglobulin
amyloidosis observed in dialysis patients [26, 27].
In this study we describe and characterize a novel oxidative
stress marker referred to as advanced oxidation protein products
(AOPP), which are present at high levels in the plasma of uremic
patients.
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Patients
One hundred nineteen patients were enrolled in the study after
giving their informed consent. They included 17 undialyzed
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patients with advanced rcnal failure defined by creatinine clear-
ance (Ccr) < 20 mI/mm (N = 17) and 102 patients receiving
dialysis for at least one year, including 25 on chronic ambulatory
peritoneal dialysis (CAPD) and 77 on maintenance hemodialysis
(HD). Hemodialysis was performed three times weekly; 47 of
the HD patients (followed at the Dialysis Center of University
Hospital, Cleveland) were treated with hollow-fiber dialyzers
equipped with polysulfone (F8 or F80; Fresenius USA, Concord,
CA, USA); these hollow-fiber dialyzers were re-used after pro-
cessing on Renatron I (Renal Systems, Minneapolis, MN, USA)
using Renalin®. The other 30 HD patients were treated with
single-use dialyzers equipped with polyacrilonitrile AN-69 mem-
branes (Hospal, Meyzieu, France) (N = 15), cellulose acetate
membranes (Baxter Laboratories, McGaw Park, IL, USA) (N =
10) or polysulfone membranes (Fresenius, Bad Homburg, Ger-
many) (N = 5). Dialysate was of standard ionic composition, and
bicarbonate was used as buffer substrate in all cases. Patients with
systemic lupus erythematosus, malignant tumors, or acute infec-
tious illnesses, and those receiving immunosuppressive therapy
were excluded from the study. Controls consisted of 41 healthy
subjects recruited among blood donors of Necker Hôpital Blood
Center.
Blood collection and plasma isolation
Blood was taken from undialyzed patients with advanced renal
failure and patients on CAPD at the time of routine laboratory
investigations. In HD patients, blood was drawn from the fistula
needle just before the start of a hemodialysis session, Blood (5 to
10 ml) was collected in standard sterile polystyrene vacuum tubes
with 5 mrvt EDTA. Following centrifugation (600 g X 10 mm) the
plasma was stored in 500 p1 aliquots at —70°C until use. Assays
were carried out on duplicate samples. As the effect of dialysis-
induced hemoconcentration on AOPP plasma levels had to be
taken into account in the study of the effect of dialysis sessions,
AOPP levels were corrected according to the total protein con-
centration,
Spectral analysis of AOPP
Spectral analysis using a Kontron UVICON 940 was performed
on plasma samples diluted 1:200 in 20 m phosphate buffer pH
7.4. Absorbance spectra in the range 200 to 400 nm were recorded
in plasma samples of HD patients and controls. Absorbance at
340 nm in acidic condition was significantly higher in plasma from
HD patients than in plasma from controls. This protocol was
adapted to a semiautomated method using a microplate reader
(Model MR 5000; Dynatech, France), and calibrated with ebb-
ramine-T (Sigma Chemical Company, St. Louis, MO, USA)
solutions which in the presence of potassium iodide absorb at 340
nm [28]. Two hundred microliters of plasma diluted 1:5 in PBS, or
chboramine-T standard solutions (0 to 100 jsmol/liter), were
placed in each well of a 96-well microtiter plate (Becton Dickin-
son Labware, Lincoln Park, NJ, USA), followed by 20 jsl of acetic
acid. Ten mieroliters of 1.16 M potassium iodide (Kb, Sigma) were
then added, followed by 20 p1 of acetic acid. The absorbance of
the reaction mixture was immediately read at 340 nm in a
microplate reader against a blank containing 200 pl of PBS, 10 p1
of Kb and 20 p1 of acetic acid. The ehloramine-T absorbance at
340 nm was linear within the range of 0 to 100 jsmol/liter. AOPP
concentrations were expressed in jsmol/liter of chloramine-T
equivalents.
Reproducibility was assessed on six plasma samples from HD
patients covering a wide range of concentrations (70 to 300
jsmol/liter). The intra-assay coefficients of variation (CV) of
quadruplicates were less than 5% and the inter-assay CV was
below 10%. It was also verified that storage of plasma at —70°C
for more than six months did not significantly affect AOPP
measurement (data not shown).
Biochemical analysis of AOPP
To test whether AOPP have oxidant properties and may
therefore be inhibited by oxidant scavengers, ascorbic acid or
methionine (range 0.01 to 100 mM) were incubated with plasma
for 15 minutes, and tested for AOPP.
Total protein concentrations using the Biuret method [29] were
measured on an Hitachi 717 analyzer (Boehringer Mannheim,
Meylan, France). Protein precipitation was performed by mixing
one volume of triehloro-acetic acid (TCA, Sigma) with one
volume of plasma. This mixture was centrifuged at 10,000 g and
AOPP determination was performed on the supernatant.
Delipidation was performed by mixing 200 p1 of plasma diluted
1/5 with the same volume of chloroform, rotated for two hours at
4°C and centrifuged at 10,000 g for 10 minutes. The lower phase
containing chloroform was discarded, while the upper phase
containing delipidated plasma was submitted to a second chloro-
form extraction and AOPP were measured in the delipidated
plasma.
Plasma fractionation by size-exclusion chromatography was
performed to determine the molecular weights of the molecules
involved in the AOPP activity. One milliter of plasma was diluted
1/5 in PBS, 10 m EDTA, pH 7.4, loaded on a chromatographic
column (1.5 x 70 cm) containing the high-performance size
exclusion matrix (Bio-Gel A 0.5 m Gel; Bio Rad, Hercules, CA,
USA) and eluted at 4°C at a flow rate of 0.2 ml/min, according to
manufacturer's instruction. For each fraction, both protein and
AOPP levels were evaluated by measuring OD at 280 nm or OD
at 340 nm in acidic condition, respectively. The column was
calibrated by loading a mixture of proteins of known molecular
weights, including thyroglobulin (669 kDa), y-globulin (150 kDa),
albumin (67 kDa) and myoglobin (17.8 kDa), the order of elution
of the mixture of proteins from the column being the inverse of
their molecular weight.
Polyactylamide gel electrophoresis (PAGE)
Nondenaturing PAGE (7.5% acrylamide) was performed in the
absence of SDS to visualize protein aggregates. Protein concen-
trations were adjusted to have 20 jig per well in sample buffer (60
mM Tris-HC1 pH 6.8, 10% glycerol, 0.05% Bromophenol Blue).
Denaturing sodium dodecyl sulfate (SDS)-PAGE was per-
formed in the presence or absence of p-mercaptoethanol. Protein
concentrations were adjusted to have 40 jig per well in sample
buffer (60 mrvi Tris-HCI pH 6.8, 10% glycerol, 0.05% Bromophe-
nob Blue, 2% SDS with or without 1% f3-mercaptoethanol).
Protein samples were boiled and run on 12.5% SDS-PAGE along
with prestained molecular weight markers (Pharmacia, Piscat-
away, NJ, USA) including phosphorylase B (94 kDa), bovine
serum albumin (67 kDa), ovalbumin (43 kDa), carbonic anhy-
drase (30 kDa) and soybean trypsin inhibitor (20 kDa). Gel were
stained with either Coomassie Brilliant Blue or silver stain
(Biorad).
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Exposure of proteins to hypochiorous acid
Control plasma or purified human serum albumin (HSA) were
exposed to increasing concentrations of HOC! (Fluka Chemika
Biochemika, Buchs, Switzerland) ranging from 0 to 50 mmol/liter.
HOC! stock solution (100 mM) was freshly prepared in PBS and
concentration was measured by spectrophotometry using a molar
extinction coefficient of 350 M ' cm' at 290 nm at pH 12 [301. In
this report, the term HOC! will be used to represent both 0C1
and its protonated form. Various concentrations of HOC! were
added to control plasma or to a solution of HSA with concentra-
tions ranging from 0 to 60 mglml incubated 30 minutes at room
temperature and tested for AOPP.
Measurement of dityrosine
As the formation of dityrosine is an index of oxidant-induced
protein cross linking and aggregation [23, 241, we measured
dityrosine level in solutions of purified HSA or control plasma
exposed to various concentrations of HOCI, and in plasma
samples from HD patients. UV and fluorescence spectra are well
established for dityrosine, with absorbance peaks at 284 nm (acid)
and 315 nm (basic) at pH 7.5, corresponding to an equilibrium
between the unionized and ionized forms of dityrosine, and a
fluorescence emission maximum at 410 nm for excitation at 315
nm [31]. Protein-bound dityrosine production was assayed by
fluorescence measurements after 200-fold dilution of the plasma
in 20 m phosphate buffer pH 7.4 in the presence of 6 M urea [25].
The fluorescence emission of dityrosine generated by the dena-
tured protein sample was recorded from 350 to 450 nm after
excitation at 315 nm using a Kontron SF 25 spectrophotometer,
and measured at its maximum near 410 nm. The assay was
calibrated by means of external standardization using a curve
generated in the same urea medium with authentic dityrosine. Its
concentration was monitored spectrophotometrically in acid me-
dium using €254 = 4.5 mM cm' [32] and in basic medium using
an absorbance ratio A315 nm/A284 nm = 1.50. Dityrosine was
synthesized by oxidation of L-tyrosine (Sigma) with horseradish
peroxidase (Sigma), and purified using the Anderson method
described in [33]. Dityrosine concentrations were normalized to
the protein concentration of each sample and expressed in
nmo!es/mg protein. intra-assay and inter-assay CV, for a given
sample were both below 10%.
Preparation of AGE-HSA and measurement of AGE pentosidine
Non-enzymatic glycation of proteins resulting in advanced
glycosylation end-products (AGEs) has been linked to protein
oxidation [341. The AGE-pentosidine, a fluorescent cross link
resulting from the reaction of pentoses with proteins [35] was
measured as a probe. Plasma protein pentosidine was determined
using a modification of the method of Odetti et a! [36]. Plasma
proteins were precipitated on ice with an equal volume of 10%
trichioroacetic acid. The pellets were washed twice with 5% cold
trichloroacetic acid and hydrolyzed in 2 m! of 6 N HC! for 16 hours
at 110°C in borosilicate tubes with screw caps. Acid was removed
by vacuum centrifugation (Savant, Farmington, NY, USA). The
hydrolyzed pellet was dissolved in 250 .tl 0.01 M heptafluorobu-
tyric acid (Sigma). The equivalent of 4 mg of plasma protein was
injected into a high-pressure liquid chromatography (HPLC)
system (Waters Division of Millipore, Marlborough, MA, USA).
A 25 x 0.46 cm C-18 Vydac type 218TP (10 .Lm) column was used
(Separations Group, Hesperia, CA, USA). HPLC was pro-
grammed with a linear gradient of 10 to 17% acetonitrile from 0
to 35 minutes. Pentosidine was eluted at approximately 30 min-
utes as monitored by fluorescence excitation at 335 nm and
emission at 385 nm. Pentosidine prepared according to the
method of Sell and Monnier [371 was used as standard. Results
were calculated per mg added protein. The intra-assay and
I
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Fig. 1. Characterization ofAOPP measurement. A. Range of linearity of AOPP measurement. Plasma samples from 5 HD patients [(U) HD1, () HD2,(El) HD3, () HD4, and (El) HD5) were successively diluted 1/2, 1/5, 1/10, 1/20 and 1/50 in PBS and AOPP levels were measured in each dilution.
Results are expressed as mean of triplicates. B. Effect of plasma TCA deproteinization, chloroform delipidation and oxidant scavengers (100 mM
ascorbic acid or 100 mi methionine) on plasma AOPP levels as described in the Methods section. Symbols are: (1112) no treatment; (U) TCA; (11:1)
chloroform; () ascorbic acid; () methionine. AOPP levels were measured in plasma samples from control subjects (N 5) and from HD patients
(N = 5) before and after each treatment. Results are expressed as mean SEM.
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struction (Sobioda, Grenoble, France) [38]. Briefly, tetraethoxy-
propane (TEP) was used as standard. Hydrolysis of each molecule
3 of TEP yields one molecule of malondialdehyde under the assay
conditions. Plasma (100 !.d) was mixed with thiobarbituric and
perchloric acids, boiled for one hour, and butanol (Farmitalia
Carlo Erba, Milan, Italy) was added. The mixture was then
vortexed and centrifuged in order to extract MDA. Fluorimetric0 measurements (excitation at 532 nm and emission at 553 nm)
were performed on supernatants using a Kontron SFM 25.
Measurement of C-reactive protein (CRP)
Plasma concentration of CRP, an acute phase protein consid-
ered as a non specific marker of inflammatory processes, was
determined by immunoturbidimetry according to manufacturer's
instruction (Orion Diagnostica, Asnières, France) on an Hitachi
717 analyzer (Boehringer Mannheim, Meylan, France).
Measurement of neopterin
Neopterin, a marker of monocyte-macrophage activation [39]
was measured using a commercial RIA according to manufactur-
er's intruction (Behring Diagnostic, Rueil-Malmaison, France).
Statistical analysis
Statistical analysis was performed using the Statistica software
0.5 package (Statsoft, Tulsa, OK, USA). Analysis of variance
0.4 (ANOVA) or Student's t-test, paired or unpaired as appropriate,
were used to detect differences between the various groups of
0.3 g patients. Simple regression analysis and Pearson r correlation0.2 coefficient were used to determine the relationships between
0 1 AOPP and dityrosine, AGE-pentosidine, TBARS, CRP or neop-
term levels. Coefficients of variation (CV) were calculated as
0.0 (standard deviation/mean) x 100. Data are expressed as mean
SEM.
Elution volume, ml
Fig. 2. Determination of AOPP molecular weights by size-exclusion chro-
matography. (A) Fractionation of plasma from a control subject (CI) and
(B) a HD patient (HD1). On each fraction, AOPP was assessed by OD at
340 nm under acidic conditions (0) and protein concentration was
assessed by OD at 280 nm (•). C. Elution profile of the molecular weight
standards including thyroglobulin (669 kDa), y-globulin (150 kDa), albu-
min (67 kDa) and myoglobin (18 kDa). Elution volume and OD at 280 nm
were measured for each collected fraction. For each standard protein, a
partition coefficient, designated Kay, was calculated as follows: Kay = (Ve
— V0)/(Vt — VO) where Ve is the elution volume of each component, VO(58 ml), the void volume, and Vt (109 ml) is the total volume. A
semilogarithmic plot of the partition coefficient on molecular weight
constitutes the linear standard curve. Fractionation was performed on 3
HD plama samples and compared with 3 controls.
inter-assay CVs for a pentosidine standard of 15 pmol were 11 and
15%, respectively.
AGE-modified HSA (AGE-HSA) was prepared by incubating
HSA (50 mg/ml) in the presence of 500 m glucose in PBS for 65
days at 37°C under sterile conditions. The resulting pentosidine
concentrations were 9 and 105 pmol/mg for HSA and AGE-HSA,
respectively.
Evaluation of lipid peroxidation by TBARS
Fluorimetric measurement of TBARS was carried out using a
commercially available kit according to the manufacturer's in-
Results
Biochemical characterization of AOPP measured in plasma
AOPP levels were significantly higher in plasma of HD patients
(N 10) than of controls (N = 10; 137.6 11.1 vs. 29.4 4.9
xmol/liter, P < 0.001). The range of linearity of AOPP measure-
ments was evaluated by testing the same plasma sample at various
dilutions. Data obtained in five plasma samples from HD patients
indicated linearity up to the dilution 1/20 (Fig. 1A). Incubation of
plasma in the presence of an oxidant scavenger such as ascorbic
acid or methionine (up to 100 mM) did not modify AOPP values,
thus showing that AOPP have no oxidant properties (Fig. 1B).
No significant difference in plasma protein concentration was
observed between controls (N = 10) and HD patients (N = 20),
67.1 1.06 versus 66.9 1.31 g/liter and no correlation between
AOPP and plasma protein concentration was observed. No AOPP
were retrieved in the supernatant after TCA treatment (Fig. 1B),
whereas delipidation of plasma by chloroform extraction halved
the AOPP level in HD patients.
Elution patterns obtained after plasma fractionation by size-
exclusion chromatography differed between HD and control
subjects. As shown in Figure 2B, in plasma from HD patients a
peak of protein was detected in the range of high molecular
weights, around 670 kDa (Fig. 2C), whereas no such protein peak
could be detected in control plasma (Fig. 2A). Interestingly, in
plasma from HD patient, this protein peak corresponded to a
A
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SDS-PAGE
A Native PAGE B + 13-mercaptoethanol
Cl C2 HD1 HD2 Cl C2 HD1 HD2 MWM
KDa
— 94
—67
—43
—30
— 20
AOPP,pmol/Iiter 15 21 346 189 15 21 346 189
Fig. 3. Electrophoresis of plasma samples from HD patients as compared to controls. A. PAGE performed under native conditions without SDS or
13-mercaptoethanol of two control samples (Cl and C2) and on two plasma samples from HD patients (HD1 and HD2). Arrows indicate protein
aggregates in the region of high molecular weights. Corresponding AOPP levels are reported at the bottom of each lane. B. PAGE performed under
denaturing conditions in the presence of SDS and f3-mercaptoethanol. The same plasma samples (Cl, C2, HD1 and HD2) were run along with standard
molecular weight markers (MWM).
A HMW-AOPP fractions B LMW-AOPP fractions
Non-reducing PAGE Reducing PAGE Reducing PAGE
MWM HD1 HD1 MWM HD1 MWM
13-ME + +
kDa
—94
94— —94
—67 —67
67—
43— —43 —43
—30
30— —30
—20
—20
20—
Fig. 4. Electrophoresis of the AOPP positive fractions obtained by size exclusion chromatography. A. Denaturing PAGE of the fraction containing high
molecular weight AOPP (HMW-AOPP). PAGE was performed on the fraction number 27 eluted at 59.6 ml (see Fig. 2B). PAGE was performed in the
absence of J3-mercaptoethanol (on the left) showing a single prominent band at 67 kDa, or in the presence of f3-mercaptoethanol (on the right) showing
several bands in addition of the 67 kDa band. B. Denaturing PAGE of the fraction containing low molecular weight AOPP (LMW-AOPP). PAGE was
performed on the fraction number 64 eluted at 142.3 ml (see Fig. 2B) in the presence of f3-mercaptoethanol showing several bands including the
prominent at 67 kDa. This electrophoresis has been performed on the fraction obtained with the plasma HD1 and similar results were obtained with
the plasma HD2.
peak of AOPP. A second peak of AOPP was detected in HD denaturing condition, no difference was observed between HD
plasma at a lower molecular weight (around 50 kDa) that partly and control plasma (Fig. 3B). PAGE together with plasma
overlapped the albumin protein peak at 280 nm. No significant fractionation suggested that plasma from HD patients exhibit high
AOPP peak could be detected in control plasma. molecular weight proteins matching the AOPP peak, which may
Native PAGE, which is supposed to preserve the multimolecu- be related to protein aggregates. The fraction corresponding to
lar structure of proteins, performed on plasma from controls or the high molecular weight AOPP peak (HMW-AOPP fraction
from dialyzed patients permits the visualization of high molecular number 27 at an elution volume of 59.65 ml, marked with an
weight species in HD patients (Fig. 3A). In contrast, under arrow on Fig. 2B) contained 1.7 mg/mi protein and treatment with
Witko-Sarsat et al: Advanced oxidation protein products in uremia 1309
HSA, mg/mi
Fig. 5. Effect of HOC1 exposure on AOPP measured in purified HSA
solution or in plasma from control subjects. A. Increasing concentrations of
HOCI were added either to a purified HSA solution (—— 60 mg/mI)
or to control plasma [(—R—) Control 1 and (—•---) Control 2] or to
chioroform-delipidated plasma [—0-— control 2 + chloroform]. B. In-
creasing concentration of HSA were exposed to 23 mivi HOC!. AOPP
measurements were performed in quadriplicate. Results (mean SEM)
are plotted on the curve.
chloroform decreased the AOPP level by 50%, thus suggesting
that lipoproteins could be part of this aggregate. However, no
lipid peroxidation products, as measured by TBARS, could be
detected (data not shown).
PAGE performed on the fraction corresponding to the HMW-
AOPP peak, in the presence of SDS to solubilize and dissociate
protein aggregates, revealed a prominent band at 67 kDa (likely
albumin) as well as a band in the high molecular weight region
that did not migrate (Fig. 4A). The same fraction submitted to
SDS-PAGE in the presence of a reducing agent such as f3-mer-
captoethanol, which can reduce disulfide bonds, showed a less
intense band in the high molecular weight region and revealed
additional bands at 78, 67 and 28 kDa that may correspond to
degradation products of oxidized albumin (Fig. 4B). Other bands
at 59 and 49 kDa were present but were also observed in the
molecular weight markers and therefore could be artifacts due to
f3-mercaptoethanol, as we previously observed [25].
The fraction corresponding to the low molecular weight AOPP
fraction (LMW-AOPP fraction number 64 at an elution volume of
142.3 ml, marked with an arrow on Fig. 2B) had a protein
concentration of 0.87 mg/ml and did not appear to contain
lipoproteins because chloroform treatment did not modify AOPP
and TBARS were undetectable (data not shown). SDS-PAGE
electrophoresis performed in the presence of -mercaptoethanol
showed an intense band at 67 kDa, likely albumin (Fig. 4B).
Taking into account the poor resolution in the range of molecular
weights below 50 kDa with the gel filtration we used, and the high
concentration of albumin in plasma, it was not surprising that the
LMW-AOPP fraction contained albumin. The contribution of
albumin to AOPP will be further discussed.
Hypochiorous acid treatment increases AOPP in purified HSA or
plasma from controls
To provide some insights into the in vivo mechanism of
30 formation of AOPP we measured AOPP in control plasma
samples submitted to increasing concentrations of HOd, a strong
oxidizing agent. We observed that AOPP level increased in a
dose-dependent manner with HOC! exposure; the same was
observed with delipidated plasma samples (Fig. 5A).
Interestingly enough, similar results were obtained when a
solution of HSA (60 mg/rn!), close to the physiologic albumin
plasma Concentration, was exposed to increasing concentrations
of HOC1 (Fig. 5A). AOPP formation also increased with albumin
concentration (Fig. 5B).
Relationships between di!yrosine and AOPP
Relationship between advanced glycation end products (AGE)
and AOPP
Because AGE formation is linked to oxidative stress, we
measured AOPP levels in a solution of purified HSA as compared
to AGE-HSA and HOC1-treated HSA, all protein concentrations
being adjusted at 10 mg/mi (Fig. 7A). We observed an increase in
AOPP levels in both AGE-HSA and HOCI-treated HSA, thus
showing that 14 mM HOCl treatment or in vitro protein glycation
were as effective to induce AOPP formation.
In vivo, AGE-pentosidine levels were higher in HD patients
(N = 47) than in controls (N = 7; 20.5 1.40 vs. 1.73 0.20
pmol/mg protein, P < 0.001, Fig. 7B). A highly significant
correlation was observed between AGE-pentosidine and AOPP
levels (r = 0.49, P < 0.001, Fig. 7C).
Relationships between AOPP and TBARS
As expected, TBARS levels were significantly increased in HD
patients (N = 42) as compared to controls (N = 20; 5.33 0.18
vs. 3.61 0.11 xm/liter, P < 0.001), but no correlation was
observed between AOPP and TBARS, thus showing that AOPP
are not directly related to lipid peroxidation.
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In vitro hypochiorous acid treatment induces dityrosine forma-
5 10 15 20 tion in purified HSA or in plasma proteins from controls (Fig.
6A). In vivo, in plasma from HD patients, the excitation spectra of
the 410 nm emission consisted of two bands centered at 317 nm
and near 285 nm (Fig. 6B), these wavelengths matching those of
the absorption bands of dityrosine at 315 and 284 nm. In contrast,
control samples were devoid of the 317 nm band characteristic of
ionized dityrosine. Dityrosine plasma levels were significantly
higher in HD patients (N = 20) than in controls (N = 10; 1.03
0.12 vs. 0.36 0.05 nmol/mg protein, P 0.004, Fig. 6C).
Moreover, a significant correlation between AOPP and dityrosine
levels was observed in vivo (r 0.63, P < 0.001, Fig. 6D).
1310 Witko-Sarsat et al: Advanced oxidation protein products in uremia
a)
c.
0
E
a)C
(I)0
O
0
E
0
Fig. 6. Relationship between dityrosine and
AOPP measurements. A. Increasing
concentrations of HOCI were added either to
control plasma (0, r = 0.98) or to a purified
HSA solution (60 mg/ml; A; r = 0.93) and
dityrosine levels were measured. B. Plasma
samples were diluted 200-fold in a urea
phosphate buffer, pH 7.4, and excitation spectra
of the emission band were recorded. Plasma
from HD patients (HD1 and HD2) showed two
peaks centered at 285 and 317 nm,
characteristics of the absorbtion bands of
dityrosine. In contrast, the peak at 317 nm is
missing in plasma sample from control subject.
Symbols are: (—) HD1; (— . —) HD2; (..'.)
Control; (———) 0.6 I.tM dityrosine. Standard
dityrosine spectra were recorded as a positive
control. C. Plasma levels of dityrosine (mean
SEM) in plasma from controls (N = 10) and HD
patients (N = 20). D. Regression analysis
between in vivo plasma levels of AOPP and
dityrosine (r = 0.63; P = 0.001).
Respective influence of uremia and dialysis procedure on
AOPP levels
To evaluate the influence of the dialysis procedure on AOPP
levels, we measured AOPP in undialyzed patients with advanced
CRF compared to patients treated by CAPD or HD (Fig. 8).
AOPP levels were significantly higher in undialyzed patients with
advanced CRF (69.4 6.6 jxmol/liter, N = 17), and even more in
CAPD patients (127.9 15.3 mol/liter, N = 25) than in controls
(33.9 3.4 xmol/liter, N = 41; P < 0.01), and were even higher
in HD patients (163.7 8.4 jxmol/liter, N = 77, P < 0.001), thus
indicating that AOPP level increases in uremia and is further
enhanced by maintenance dialysis. Of note, AOPP levels were not
influenced by diabetes mellitus, as no difference between diabetics
and non-diabetics was found in CAPD or HD patients.
In the group of HD patients treated in the same center (Necker
Hôpital) with single-use high-flux dialyzers, AOPP levels at start
of hemodialysis sessions were not significantly influenced by the
nature of the dialysis membrane {153.4 19.1 xmol/liter (N = 5),
195,2 24.2 xmol/liter (N = 10) and 140.8 17.9 xmol/liter(N = 15), respectively for cellulose acetate, polysulfone, and
polyacrilonitrile AN69 membranes]. AOPP levels measured at the
beginning and at the end of a single dialysis session in 10 patients
treated with polysulfone membranes were 223.6 19.8 versus
267.5 16.5 mol/liter (P < 0.05).
Relationships between AOPP and CRP or neopterin
Plasma levels of CRP were significantly higher in plasma from
HD patients (N 44) than from controls (N = 10; 24.2 4.2 vs.
1.7 0.67 mg/mi, P < 0.001). However, no correlation was
observed between AOPP and CRP levels (r = 0.28, P = 0.12).
Plasma levels of neopterin, a marker of monocyte activation,
were significantly elevated in patients with advanced CRF (32
4 nmol/liter, N = 17), on CAPD (82 4 nmol/liter, N = 25) or on
HD (149 14 nmol/liter, N = 47) as compared to controls (1.5
0.5 nmol/liter, N = 41;P < 0.001 for all). In uremic patients, there
was a highly significant correlation between neopterin and AOPP
levels (r = 0.59,P < 0.00 1; Fig. 9). Interestingly, such a correlation
was not found between neopterin and TBARS or neopterin and
CRP.
The possibility that the correlation between AOPP and neop-
term was only artifactual, in particular due to the absorbance of
neopterin at 340 nm, was ruled out by an in vitro experiment
showing that increasing concentrations of neopterin (up to 20-fold
the level found in HD plasma) added to normal or uremic plasma
did not increase AOPP concentrations (data not shown).
Discussion
The present study describes a novel oxidative stress marker,
referred to as advanced oxidation protein products (AOPP) and
its possible clinical relevance in chronic uremia. In vitro, AOPP
can be formed in purified HSA solution as well as in control
plasma following HOC1 exposure. In vivo, plasma levels of AOPP
closely correlate with levels of dityrosine, a hallmark of oxidized
proteins, and with pentosidine, a marker of enzymatic protein
glycation tightly related to oxidative stress. We thus afford evi-
dence for the first time that oxidant-mediated protein damage
occurs in plasma from uremic patients. Plasma levels of AOPP
were the highest in patients on hemodialysis, followed by those on
peritoneal dialysis. Undialyzed patients with advanced chronic
renal failure had lower levels than those on dialysis but markedly
higher than healthy controls. We further demonstrated that in
undialyzed CRF patients, AOPP level is in close relationship with
plasma concentration of neopterin, a marker of monocyte activa-
tion.
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Although the implication of oxidative stress in the pathophys-
iology of uremia has been suggested, little is known about the
underlying mechanisms and a number of questions still remain to
be solved. What is the respective influence of uremia and hemo-
dialysis? What are the relationships with the chronic inflammatory
state and the immune dysfunction associated with uremia? What
are the relationships with clinical complications such as athero-
sclerosis and/or J32-microglobulin amyloidosis? To date, evalua-
tion of lipid peroxidation and of antioxidant systems has not
provided reliable and sensitive tools to answer these questions.
Biochemical characterization of the species measured in our
assay revealed that two distinct peaks at 670 and around 70 kDa
account for the total AOPP level in plasma. Protein electrophore-
sis showed that the high molecular weight AOPP peak is mostly
due to albumin that appears to form aggregates likely resulting
from disulfide bridges and/or dityrosine cross linking. Likewise,
the low molecular weight AOPP peak also contains albumin in its
monomeric form. Interestingly, the molecular weight of the
aggregates (670 kDa) is ten times that of monomeric albumin (67
kDa). Our AOPP assay does not react with non-oxidized native
Neopterin, nmol/liter
Fig. 9. Relationship between AOPP and neopterin. Regression analysis
between plasma levels of AOPP and neopterin. Data are from 85 subjects
including 17 patients with advanced CRF, 25 CAPD patients and 43 HD
patients (r = 0.59; P = 0.0001).
serum albumin, as evidenced by studies using purified HSA
solutions or control plasma, or by plasma fractionation showing
that the AOPP peak does not exactly match the albumin peak. On
the other hand, we provide demonstration that oxidatively mod-
ified albumin leads to AOPP formation. Two interpretations are
possible: either the low molecular weight-AOPP fraction may
contain structurally and oxidatively-modified albumin that posi-
tives the AOPP assay; or alternatively, low molecular weight-
AOPP are derived from other plasma proteins. Previous studies
had shown that the numerous thiol groups of albumin account for
the major antioxidant capacity of normal human plasma toward
H202 or HOCI and that high concentrations of these oxidants are
needed to form protein carbonyl [30]. This is in keeping with our
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Fig. 8. Plasma AOPP levels in undialyzed uremic patients, CAPD and HD
patients as compared to controls. Plasma AOPP levels were measured in
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compared to controls. Mean are indicated by horizontal lines. Differences
between uremic patients and controls and between CAPD and HD
patients are significant at P < 0.001.
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own data showing that for a solution of 60 mg/mI HSA or normal
plasma, a minimum concentration of 5 mmol/liter HOCI is
required to generate AOPP, Taking together, these data strongly
suggest that AOPP measure highly oxidized proteins and espe-
cially albumin.
It is now well known that neutrophil-derived oxidants can alter
the primary, secondary or tertiary structure of proteins to cause
denaturation, increased hydrophobicity leading to protein frag-
mentation [40] and, at extremely high levels, protein cross linking.
Such cross-linked products are less susceptible to proteolytic
digestion and would be expected to form insoluble aggregates, as
has been reported for many proteins including albumin [24]. The
fact that AOPP levels positively correlate with dityrosine further
supports the relevance of AOPP as an in vivo marker of oxidant-
mediated protein damage [41]. With respect to the correlation
between AOPP and the AGE-pentosidine, taken as a probe for
the advanced Maillard reaction in vivo, the following comments
can be made: increasing evidence links the Maillard reaction to
oxidative pathway of injury to biological molecules both in vivo
and in vitro as demonstrated by the inhibition of the formation of
pentosidine in the absence of oxygen or in the presence of oxidant
scavengers [341. Conversely, glucose autooxidation proceeds with
the release of free radicals and hydrogen peroxide thus potenti-
ating the formation of AGEs [42]. Moreover, pentosidine levels
correlate with the degree of renal failure and further increase on
hemodialysis [43, 44].
The influence of lipids on AOPP determination is still not clear.
In vitro, iipids are not necessary to form AOPP in a control plasma
exposed to Hod. In contrast, delipidation of plasma samples
containing high concentrations of in vivo-formed AOPP halved
AOPP level and plasma level of lipids or lipid peroxidation
markers such as TBARS did not correlate with AOPP levels. The
current explanation is that lipids are not necessary but may
enhance the in vivo process of AOPP formation. Taking into
account the fact that the oxidative modification of LDL is an
important factor in the development of atherosclerosis [45], it is
highly probable that AOPP and oxidized lipoproteins act in
concert in this process.
Among the new analytical and biological approaches to inves-
tigate the complex mechanisms leading to uremia-related oxida-
tive stress, electron spin resonance spectroscopy recently allowed
to evidence the presence of oxidants in uremic plasma [461.
Oxidants were detected by their capacity to oxidize the spin trap
3,5-dibromo-4-nitrosobenzene sulphonate (DBNBS). Although
these oxidants have yet to be isolated and precisely identified,
available evidence indicates that they are dialyzable with an upper
molecular weight limit of about 3 kDa, and they can be scavenged
by high concentrations of ascorbic acid or glutathione [46]. The
complexity of this technique, however, precludes its availability
for clinical practice. In contrast, the methodology we propose,
based on a spectrophotometric assay appears more simple and
could easily be transferable from research to clinical laboratory
investigation.
With respect to the possible pathophysiological significance of
AOPP in the uremia-related immuno-infiammatory state, we
found no relationship between AOPP levels and those of CRP as
a nonspecific marker of inflammation. In contrast, plasma level of
AOPP was positively correlated with that of neopterin which as we
previously reported, closely reflects the monocyte activation state
associated with chronic uremia [3]. Indeed, in this previous study
we found that plasma levels of neopterin increased with the
progression of chronic uremia in parallel with circulating levels of
monocyte-derived pro-inflammatory cytokines or their specific
inhibitors (including IL-i and IL-i receptor antagonist, TNF-a
and its soluble receptors) as well as with those of T cell and B cell
activation markers. The fact that the correlation between neop-
term and monocyte-derived proinflammatory cytokines but not T
or B cell activation markers persisted after adjustment of both
parameters on creatinine clearance values suggests that neopterin
accumulation is not solely explained by the loss of renal function
and thus reflects the monocyte-macrophage activation related to
uremia.
In conclusion, oxidant-induced protein damage appears to be
an important component in the complex pathophysiology of the
uremia-related immunoinflammatory disorder and could there-
fore take a part in uremic toxicity [47].
Acknowledgments
This work was supported by grants from the Extramural Grant Program,
Baxter Corporation (MF and BDL) and by DK-45619 from the National
Institute of Health (MF). We thank Francoise Tresset for skillful technical
assistance, and Mathilde Labrunie, M.S. for statistical analysis.
Reprint requests to Beatrice Descamps-Latscha M.D., Ph.D., INSERM
U25, Hôpital Necker, 161 rue de Sèvres, 75743 Paris CEDEX 15, France.
References
1. DESCAMPS-LATSCI-IA B, HERBELIN A, NGUYEN AT, ZINGRAFF J,
JUNGERS P, CHATENOUD L: Immune system dysregulation in uremia.
Semin Nephrol 14:253—260, 1994
2. PEREIRA BJG, SiiPIRo L, KING AJ, FALAGAS ME, STROM JA,
DNARELLO CA: Plasma levels of 1L1J3, TNFcs and their specific
inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis
patients. Kidney mt 45:890—896, 1994
3. DESCAMPS-LATSCHA B, HERBELIN A, NGUYEN AT, ROUX-LOMBARD P.
ZINGRAFF J, MOYNOT A, VERGER C, DAHMANE D, DE GROOTE D,
JUNGERS P, DAYER JM: Balance between IL-i beta, TNF-alpha, and
their specific inhibitors in chronic renal failure and maintenance
dialysis. Relationships with activation markers of T cells, B cells, and
monocytes. J immunol 154:882—892, 1995
4. WARD RA: Phagocytic cell function as an index of biocompatibility.
Nephrol Dial Transplant 9(Suppl 2):46—56, 1994
5. NGUYEN AT, LETHIAS C, ZINGRAFF J, HERBELIN A, NARET C,
DESCAMPS-LATSCHA B: Hemodialysis membrane-induced activation of
phagocyte oxidative metabolism detected in vivo and in vitro within
microamounts of whole blood. Kidney mt 28:158—167, 1985
6. PAUL JL, ROCH-ARVEILLER M, ATGER V, M NK, LUONG N,
MoArrI N, RAICHVARG D: Human polymorphonuclear leukocyte
oxidative metabolism in uremic patients: A longitudinal study. Artif
Oigans 14(Suppl 3):57—62, 1990
7. HIMMELFARB J, LAZARUS JM, HAKIM R: Reactive oxygen species
production by monocytes and polymorphonuclear leukocytes during
dialysis. Am J Kidney Dis 17:271—276, 1991
8. MARKERT M, HEIERLI C, KUWAHARA T, FREI J, WAUTERS JP:
Dialyzed polymorphonuclear neutrophil oxidative metabolism during
dialysis: A comparative study with 5 new and reused membranes. Clin
Nephrol 29:129—136, 1988
9. DESCAMPS-LATSCHA B, GOLDFARB B, NGUYEN AT, LANDAIS P, LON-
DON G, HAEFFNER-CAVAILLON N, JACQUOT C, HERBELIN A, KAZATCH-
KINE M: Establishing the relationship between complement activation
and stimulation of phagocyte oxidative metabolism in hemodialyzed
patients: A randomized prospective study. Nephron 59:279—285, 1991
10. CRISTOL JP, CANAUD B, RABESANDRATANA H, GAILLARD I, SERRE A,
MION C: Enhancement of reactive oxygen species production and cell
surface markers expression due to haemodialysis. Nephrol Dial Trans-
plant 9:389—394, 1994
Witko-Sarsat et al: Advanced oxidation protein products in uremia 1313
ii. LouoiiREY CM, YOUNG IS, LIGHTBODY Jil, MCMASTER D, Mc-
NAMEE PT, TRIMBLE ER: Oxidative stress in haemodialysis. Quart J
Med 87:679—683, 1994
12. PONKA A, KIJHLBACK B: Serum ascorbic acid in patients undergoing
chronic hemodialysis. Acta Med Scand 213:305—307, 1983
13. SHAINKIN-KESTENBAUM R, CARUSO C, BERIXNE GM: Reduced super-
oxide dismutase activity in erythrocytes of dialysis patients: A possible
factor in the etiology of uremic anemia. Nephron 55:251—253, 1990
14. JACOBSON Sf1, Mol.DEus P: Whole blood-, plasma- and red blood cell
glutathione and cysteine in patients with kidney disease and during
hemodialysis, Clin Nephrol 42:189—192, 1994
15. ScillAvoN R, BIAsIOLI S, DE FANTI E, PETROSINO L, CAvA.LLINI L,
CAVALCANTI G, ZAMBELLO A, GuIDI G: The plasma glutathione
peroxidase enzyme in hemodialyzed subjects. ASAJO J 40:968—971,
1994
16. RICHARD MJ, ARNAUD J, JuRK0vITZ C, HACHACHE T, MEFTAHI H,
LAPORTE F, FORET M, FAVILiR A, CORDONNIER D: Trace elements and
lipid peroxidation abnormalities in patients with chronic renal failure.
Nephron 57:10—15, 1991
17. WITZTUM JL: The oxidation hypothesis of atherosclerosis. Lancet
344:793—795, 1994
18. UNDER A, CHARRA B, SI-IERRARD DJ, SCRIBNER BH: Accelerated
atherosclerosis in prolonged maintenance hemodialysis. N EngI J Med
290:698—701, 1974
19. MAIIIoux LU, BELLUCCI AG, WILKES BM, NAPOUTANO B, MOSSEY
RT, LESSER M, BLUESTONE PA: Mortality in dialysis patients: Analysis
of the causes of death. Am J Kidney Dis 18:326—335, 1991
20. RITz E, Dio'piscH R, STIER E, HANSCH G: Atherogenesis and cardiac
death: Are they related to dialysis procedure and biocompatibility?
Nephrol Dial Transplant 9(Suppl 2):165—172, 1994
21. FILLII H, EIION E, SULLIVAN J, SHERMAN R, ZABRISKIE JB: Thiohar-
hituric acid reactive material in uremic blood. Nephron 29:40—43,
1981
22. MAHER ER, WIcKENS DG, GRIFFIN JF, KYLE F, CURTIS JR. D0R-
MANDY TL: Increased free-radical activity during haemodialysis?
Wephrol Dial Transplant 2:169—171, .1987
23. WOLFF SP, GARNER A, DEAN RT: Free radicals, lipids and protein
degradation. Trends Biochem Sci 11:27—31, 1986
24. DAVIEs U: Protein damage and degradation by oxygen radicals. I.
general aspects. J Biol Chem 262:9895—9901, 1987
25. CAPEILLERE-BIANDIN C, DELAVEAU T, DESCAMPS-LATSCHA B: Struc-
tural modifications of human beta 2 microglohulin treated with
oxygen-derived radicals. Biochem J 277:175—182, 1991
26. v YPERSELE C, JADOuL M, MALOHEM J, MALDAGUE B, JAMART J:
Effect of dialysis membrane and patient's age on signs of dialysis-
related amyloidosis. Kidney mt 39:1012—1019, 1991
27. KOCH KM: Dialysis-related amyloidosis. Kidney In! 41:1416—1429,
1992
28. WITKO V, NGUYEN AT, DESCAMPS-LATSCI-IA B: Microtiter plate assay
for phagocyte-derived taurine-chloramines. J Clin Lab Anal 6:47—53,
1992
29. DOUMAS BT, BAYSE DD, CARTER RJ, PETERS T JR, SCIIAFFER R: A
candidate reference method for determination of total protein in
serum. I. Development and validation. Clin Chem 27:1642—1650, 1981
30. VAN DER VOLT A, HU M-H, O'NEILL CA, CROSS CE, HALLIWELI B:
Interactions of human blood plasma with hydrogen peroxide and
hypochiorous acid. J Lab Clin Med 124:701—707, 1994
31. LEHRER SS, FASMAN GD: Ultraviolet irradiation effects in poly-L-
tyrosine and model compounds. Identiflcatio of bityrosine as a
photoproduct. Biochemistiy 6:757—767, 1967
32. GROSS AJ, SIzER LW: The oxidation of tyramine, tyrosine and related
compounds by peroxidase. J Biol Chem 234:1611—1616, 1959
33. AMADO R, AESCIIBACH R, NEUKOM H: Dityrosine: In vitro production
and characterization. Meth Enzymol 107:377—388, 1984
34. BAYNFS JW: Role of oxidative stress in development of complications
in diabetes. Diabetes 40:405—412, 1991
35. MONNIER VM, SELL DR, NAGARAJ RH, MIYATA 5, GRANDFIEE S,
ODE1TI P, IBRAI IIM SA: Maillard reaction-mediated molecular dam-
age to extracellular matrix and other tissue proteins in diabetes, aging,
and uremia. Diabetes 41(Suppl 2):36—41, 1992
36. ODETrI P, FOGARly J, SELL DR, MONNIER VM: Chromatographic
quantitation of plasma and erythrocyte pentosidine in diabetic and
uremic subjects. Diabetes 41:153—159, 1992
37. SELL DR, MONNIER VM: Structure elucidation of a senescence
cross-link from human extracellular matrix. Implication of pentoses in
the aging process. J Biol Chem 264:21597—21602, 1989
38. RICHARD MJ, PORTAL B, MEO J, COUDRAY C, HADJIAN A, FAVIER A:
Malondialdehyde kit evaluated for determining plasma and lipopro-
tein fractions that react with thiobarbituric acid. Clin Chem 38:704—
709, 1992
39. FUCHS D, IIAUSEN A, REIBNEGGER G, WERNER ER, VON DrI-rRICH F,
WAd rIER H: Neopterin levels in long-term hemodialysis. Glin Nephrol
30:220—224, 1988
40. DAVIES U, UN SW, PACIIICI RE: Protein damage and degradation by
oxygen radicals. IV. Degradation of denatured protein. J Biol Chem
262:9914—9920, 1987
41. HEINECKE JW, LI W, DAEFINKE HD, GOLDSTEIN JA: Dityrosine, a
specific marker of oxidation, is synthesized by the myeloperoxidase-
hydrogen peroxide system of human neutrophils and macrophages. J
Biol Chem 268:4069—4077, 1993
42. WOLFF SP, JIANG ZY, Html JV: Protein glycation and oxidative stress
in diabetes mellitus and ageing. Free Rad Biol Med 10:339—352, 1991
43. MAKITA Z, BUCALA R, RAYFIELD EJ, FRIEDMAN F.A, KAUFMAN AM,
KORBET SM, BARTH RH, WINStoN JA, FUn H, MANOGUE KR,
CERAMI A: Reactive glycosylation endproducts in diabetic uraemia
and treatment of renal failure. Lancet 343:1519—1522, 1994
44. FRIEDLANDER MA, Wu YC, SCHUIAKJA, MONNIER VM, HRICIKDE:
Influence of dialysis modality on plasma and tissue concentrations of
pentosidine in patients with end stage renal disease. Am J Kidney Dis
25:445—45l, 1995
45. MAGGI E, BELLAZZI R, FALASCHI F, FRArFONI A, PERANI G, FINARDI
0, GAZO A, NAt M, ROMANINI D, BELLOMOG: Enhanced LDL
oxidation in uremic patients: An additional mechanism for acceler-
ated atherosclerosis? Kidney mt 45:876—883, 1994
46. ROSELAAR SE, NAZHAT NB, WINYARD PG, JONES F, CUNNINGHAM J,
BLAKE DR: Detection of oxidants in uremic plasma by electron spin
resonance spectroscopy. Kidney mt 48:199—206, 1995
47. VANHOLDER R, DL SMET R, Hsu C, VOGELEERE F, RINGOIR S: Uremic
toxicity: The middle molecule hypothesis revisited. Semin Nephrol
14:205—231, 1994
